코오롱티슈진

950160KOSDAQ

49.8 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment16.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.4% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Koongtishujin is a biotech company developing cell gene therapy drugs using its TG-C platform, currently conducting Phase III clinical trials for knee osteoarthritis and Phase II trials for hip osteoarthritis. As of July 2024, the Phase III trial for knee osteoarthritis has enrolled 1,066 patients. The company also operates a complex distribution business, selling health supplements, cosmetics, and wines through its W-store and L&B segments.

Number of Employees

58people

Average Salary

163.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-188.19Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.60Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.3% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼0.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -77.0% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 3Neutral 2Negative 4Average Sentiment Score 65

Negative
신약 파이프라인 세계 3위인데… K바이오 막아선 ‘3상의 벽’
코오롱티슈진의 신약 파이프라인이 세계적 수준이지만, 엄격한 임상 3상 과정으로 인해 투자 리스크가 커져 부정적 영향이 예상됩니다.
Negative
"가짜약이 통증 더 줄였다?"…'인보사' 美 임상서 무슨 일이
임상 결과에 대한 의문이 제기되어 코오롱티슈진의 인보사 관련 신뢰도 하락.
Neutral
"아직 끝난 게 아니다"…13조 관절염치료제 시장 '게임체인저' 될까 ...
기사 내용은 코오롱티슈진의 임상 진행 상황을 다루지만, 직접적인 주식 영향은 명시되지 않았습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 17,420Won52-week high 138,80052-week low 11,670

1-month return3.0Point

1m -1.36% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14